Zhang T, Li W, Chen Q, He W, Sun J, Li D
Front Immunol. 2024; 15:1508028.
PMID: 39726604
PMC: 11669689.
DOI: 10.3389/fimmu.2024.1508028.
Ye G, Ye M, Jin X
Am J Cancer Res. 2024; 14(9):4113-4171.
PMID: 39417171
PMC: 11477829.
DOI: 10.62347/UJVP4361.
Saeki I, Shimose S, Tomonari T, Ito T, Tani J, Takeuchi Y
PLoS One. 2024; 19(9):e0311084.
PMID: 39321197
PMC: 11423983.
DOI: 10.1371/journal.pone.0311084.
Kuzuya T, Kawabe N, Muto H, Wada Y, Komura G, Nakano T
Curr Oncol. 2024; 31(8):4225-4240.
PMID: 39195298
PMC: 11353012.
DOI: 10.3390/curroncol31080315.
Muller L, Bender D, Gairing S, Foerster F, Weinmann A, Mittler J
Sci Rep. 2024; 14(1):16550.
PMID: 39019953
PMC: 11255265.
DOI: 10.1038/s41598-024-67312-2.
Prognostic Value of Alpha-Fetoprotein in Unresectable Hepatocellular Carcinoma Treated with Hepatic Artery Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab.
Xiao Y, Chen W, Deng W, Zhu G, Xie J, Luo L
J Hepatocell Carcinoma. 2024; 11:1251-1263.
PMID: 38979083
PMC: 11228324.
DOI: 10.2147/JHC.S460922.
A Multicenter Phase 2 Trial Evaluating the Efficacy and Safety of Preoperative Lenvatinib Therapy for Patients with Advanced Hepatocellular Carcinoma (LENS-HCC Trial).
Ichida A, Arita J, Hatano E, Eguchi S, Saiura A, Nagano H
Liver Cancer. 2024; 13(3):322-334.
PMID: 38894811
PMC: 11185855.
DOI: 10.1159/000535514.
Real-World Effectiveness of First Line Lenvatinib Therapy in Advanced Hepatocellular Carcinoma: Current Insights.
de Castria T, Kim R
Pragmat Obs Res. 2024; 15:79-87.
PMID: 38881691
PMC: 11178097.
DOI: 10.2147/POR.S395974.
Early Tumor Marker Response Predicts Treatment Outcomes in Patients with Unresectable Hepatocellular Carcinoma Receiving Combined Lenvatinib, Immune Checkpoint Inhibitors, and Transcatheter Arterial Chemoembolization Therapy.
Luo M, Wu J, Wu J, Lin Z, Li Y, Zeng Z
J Hepatocell Carcinoma. 2023; 10:1827-1837.
PMID: 37850079
PMC: 10578160.
DOI: 10.2147/JHC.S425674.
Early Prediction of Response Focused on Tumor Markers in Atezolizumab plus Bevacizumab Therapy for Hepatocellular Carcinoma.
Tanabe N, Saeki I, Aibe Y, Matsuda T, Hanazono T, Nishi M
Cancers (Basel). 2023; 15(11).
PMID: 37296889
PMC: 10251947.
DOI: 10.3390/cancers15112927.
Machine Learning to Predict the Response to Lenvatinib Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma.
Ma J, Bo Z, Zhao Z, Yang J, Yang Y, Li H
Cancers (Basel). 2023; 15(3).
PMID: 36765583
PMC: 9913670.
DOI: 10.3390/cancers15030625.
Association between early response of alpha-fetoprotein and treatment efficacy of systemic therapy for advanced hepatocellular carcinoma: A multicenter cohort study from China.
Hou G, Liu B, Fan Z, Li C, Zhang J, Guo Y
Front Oncol. 2023; 12:1094104.
PMID: 36686731
PMC: 9846773.
DOI: 10.3389/fonc.2022.1094104.
Artificial intelligence based on serum biomarkers predicts the efficacy of lenvatinib for unresectable hepatocellular carcinoma.
Hsu P, Liang P, Chang W, Lu M, Wang W, Chuang S
Am J Cancer Res. 2023; 12(12):5576-5588.
PMID: 36628276
PMC: 9827079.
Safety and Effectiveness of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice: An Observational Post-Marketing Study in Japan.
Furuse J, Izumi N, Motomura K, Inaba Y, Katamura Y, Kondo Y
Drugs Real World Outcomes. 2023; 10(2):195-205.
PMID: 36602748
PMC: 10232401.
DOI: 10.1007/s40801-022-00348-w.
Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights.
Cammarota A, Zanuso V, Pressiani T, Personeni N, Rimassa L
J Hepatocell Carcinoma. 2022; 9:1011-1027.
PMID: 36128575
PMC: 9482774.
DOI: 10.2147/JHC.S268293.
Targeted Therapy for Hepatocellular Carcinoma: Old and New Opportunities.
Laface C, Fedele P, Maselli F, Ambrogio F, Foti C, Molinari P
Cancers (Basel). 2022; 14(16).
PMID: 36011021
PMC: 9406380.
DOI: 10.3390/cancers14164028.
Combination of CRAFITY score with Alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
Teng W, Lin C, Su C, Lin P, Hsieh Y, Chen W
Am J Cancer Res. 2022; 12(4):1899-1911.
PMID: 35530282
PMC: 9077079.
Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma.
Zhu A, Dayyani F, Yen C, Ren Z, Bai Y, Meng Z
Clin Cancer Res. 2022; 28(16):3537-3545.
PMID: 35435967
PMC: 9662926.
DOI: 10.1158/1078-0432.CCR-21-3275.
Dynamic Change of Albumin-Bilirubin Score Is Good Predictive Parameter for Prognosis in Chronic Hepatitis C-hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization.
Lin P, Teng W, Jeng W, Chen W, Hsieh Y, Huang C
Diagnostics (Basel). 2022; 12(3).
PMID: 35328217
PMC: 8947376.
DOI: 10.3390/diagnostics12030665.
Early Alpha-Fetoprotein Response Is Associated With Survival in Patients With HBV-Related Hepatocellular Carcinoma Receiving Lenvatinib.
Liu B, Shang X, Shi J, Cui G, Li X, Wang N
Front Oncol. 2022; 12:807189.
PMID: 35251977
PMC: 8893311.
DOI: 10.3389/fonc.2022.807189.